Sutro Biopharma

Sutro Biopharma: Focused on developing next generation antibody drug conjugates (ADCs) and multi-specific antibody-based therapeutics for cancer therapy. The company’s discovery and development efforts are driven by its scalable cell-free protein expression platform (Xpress CF) that enables rapid and systematic evaluation of protein structure-activity relationships. Sutro has three wholly-owned ADCs that are on clinical pathways and three high value collaborations with BMS, Merck, and EMD Serono. STRO-001, anti-CD74 ADC, for multiple myeloma and lymphomas is in Phase 1 and showed encouraging initial safety data at EHA & ASH 2019 – additional NHL cohort data will be presented at ASH 2020 and a dose expansion of Ph 1 expected to begin enrolling 1H21. STRO-002 for ovarian and endometrial cancer is also in a Phase 1 trial. At the AACR-NCI-EORTC conference in October 2019, STRO-002 data showed it was well tolerated and demonstrated it’s clinically efficacious at multiple doses (starting at 2.9 mg/kg). Additional Phase 1 data expected during a KOL in 4Q20 and dose-expansion of Ph 1 trial is expected to begin enrolling in 4Q20.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - Pacific
Clinical Stage
Phase l or ll
Disease Space
Autoimmune, Infectious Disease, Oncology
Industry
Biotechnology
Listing
Public, USA
Market Cap
1B +
Therapeutic Modalities
Antibodies, Platform Technology
Website:
Address:
310 Utah Ave
Suite 150
South San Francisco, CA 94080
United States

Company Participants at Solebury Trout Virtual Management Access Event 2021

Bill Newell
Sutro Biopharma, Chief Executive Officer
Mr. Newell has over 24 years of senior management experience in the biotechnology industry. He joined Sutro Biopharma as CEO in January 2009. Previously, he served as the President of Aerovance, Inc., a venture-backed company developing clinical assets for respiratory diseases. Mr. Newell also was Chief Business Officer and Senior Vice President at publicly-traded QLT, Inc. and served in several senior management positions at public-traded Axys Pharmaceuticals, Inc. For the 16 years prior to joining Axys, Mr. Newell practiced corporate law in the San Francisco Bay Area. He is presently a member of the Board at Symic Bio, Inc. Mr. Newell is also a Board member on BIO

Top 10 Holders of Sutro Biopharma, Inc.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Ecor1 Capital LLC 13.48 3,113,617 85.75 13F 9/30/20
BVF, Inc. 13.37 3,087,195 85.02 13F 9/30/20
BVF Partners LP 5.20 2,368,392 65.23 Stakes 5/22/20
Franklin Advisers, Inc. 9.33 2,155,239 59.36 Funds 12/31/20
RA Capital Management LP 9.17 2,118,212 58.34 13F 9/30/20
Ridgeback Capital Management LP 8.73 2,014,687 55.48 Stakes 8/13/20
Eventide Asset Management LLC 8.60 1,985,975 54.69 13F 9/30/20
SV Health Investors LLC 7.90 1,824,542 50.25 13F 9/30/20
The Vanguard Group, Inc. 7.54 1,742,023 47.98 Funds 12/31/20
Baillie Gifford & Co. 7.34 1,695,654 46.70 13F 9/30/20
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2021 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.